An observational study in Heart Failure, sponsored by Wonju Severance Christian Hospital. Status unknown at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Wonju Severance Christian Hospital · Observational
Several surrogate biomarkers including natriuretic peptide(NP), and growth differentiation factor-15(GDF-15) and ST2 has prognostic significance in heart failure(HF), and reductions in its value may predict clinical improvement. However, there are limited data regarding the prognostic value of these biomarkers during short-term follow-up after discharge in acute decompensated heart failure. The purpose of this study is to evaluate the prognostic value of short-term follow-up surrogate biomarkers for predicting prognosis of hospitalized patients with acute decompensated heart failure.
5,803 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.
This study's planned enrollment of 1,500 is above the median of 200 across 1,719 observational studies indexed under Heart Failure.
Browse Heart Failure studies →Wonju Severance Christian Hospital is the lead sponsor of 43 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Hospitalized patients with acute decompensated heart failure
Inclusion Criteria: the diagnosis of Heart failure requires the following
Exclusion Criteria:
The incidence rate (%) of composite endpoint including cardiovascular mortality or hospital readmission
Cardiovascular mortality: death due to heart failure aggravation, arrhythmia, cerebrovascular events, myocardial infarction. Hospital readmission: any readmission
Time frame: 12 months
The incidence rate (%) of all cause mortality
Any death after enrollment
Time frame: 12 months
The incidence rate (%) of cardiovascular mortality
Death due to heart failure aggravation, arrhythmia, cerebrovascular events, myocardial infarction.
Time frame: 12 months
The incidence rate (%) of hospital readmission
Any readmission after discharge
Time frame: 12 months
The incidence rate (%) of hospital readmission due to heart failure aggravation
Readmission due to heart failure aggravation after discharge
Time frame: 12 months
The incidence rate (%) of cerebrovascular events
Stroke or intracranial hemorrhage
Time frame: 12 months
The incidence rate (%) of acute coronary syndrome
Unstable angina or myocardial infarction
Time frame: 12 months
Plan to share: No
Started Feb 2021 (actual). Primary completion is estimated for Dec 2024, 46 months after the start.
Of 665 non-industry observational studies under Heart Failure, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 89. This study's planned 46 months is close to that.
Counting every sponsor, half of 825 studies reached it within 40 months; a quarter within 21 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wonju Severance Christian Hospital